Heterozygous and homozygous gene knockout of the 5-HT1B receptor have different effects on methamphetamine-induced behavioral sensitization.
Journal
Behavioural pharmacology
ISSN: 1473-5849
Titre abrégé: Behav Pharmacol
Pays: England
ID NLM: 9013016
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
pmc-release:
01
10
2024
medline:
18
9
2023
pubmed:
5
9
2023
entrez:
5
9
2023
Statut:
ppublish
Résumé
The psychostimulant drug methamphetamine (METH) causes euphoria in humans and locomotor hyperactivity in rodents by acting on the mesolimbic dopamine (DA) pathway and has severe abuse and addiction liability. Behavioral sensitization, an increased behavioral response to a drug with repeated administration, can persist for many months after the last administration. Research has shown that the serotonin 1B (5-HT1B) receptor plays a critical role in the development and maintenance of drug addiction, as well as other addictive behaviors. This study examined the role of 5-HT1B receptors in METH-induced locomotor sensitization using 5-HT1B knockout (KO) mice. To clarify the action of METH in 5-HT1B KO mice the effects of METH on extracellular levels of DA (DAec) and 5-HT (5-HTec) in the caudate putamen (CPu) and the nucleus accumbens (NAc) were examined. Locomotor sensitization and extracellular monoamine levels were determined in wild-type mice (5-HT1B +/+), heterozygous 5-HT1B receptor KO (5-HT1B +/-) mice and homozygous 5-HT1B receptor KO mice (5-HT1B -/-). Behavioral sensitization to METH was enhanced in 5-HT1B -/- mice compared to 5-HT1B +/+ mice but was attenuated in 5-HT1B +/- mice compared to 5-HT1B +/+ and 5-HT1B -/- mice. In vivo, microdialysis demonstrated that acute administration of METH increases DAec levels in the CPu and NAc of 5-HT1B KO mice compared to saline groups. In 5-HT1B +/- mice, METH increased 5-HTec levels in the CPu, and DAec levels in the NAc were higher than in others.5-HT1B receptors play an important role in regulating METH-induced behavioral sensitization.
Identifiants
pubmed: 37668157
doi: 10.1097/FBP.0000000000000745
pii: 00008877-990000000-00061
pmc: PMC10527357
mid: NIHMS1914487
doi:
Substances chimiques
Methamphetamine
44RAL3456C
Receptor, Serotonin, 5-HT1B
0
Central Nervous System Stimulants
0
Dopamine
VTD58H1Z2X
Serotonin
333DO1RDJY
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
393-403Subventions
Organisme : NIDA NIH HHS
ID : UG3 DA056039
Pays : United States
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Neuropsychopharmacology. 2004 Oct;29(10):1790-9
pubmed: 15226739
Nature. 1998 May 14;393(6681):175-8
pubmed: 9603521
Neuropharmacology. 2002 Jun;42(7):941-9
pubmed: 12069904
Neuropsychopharmacology. 2002 Jan;26(1):40-52
pubmed: 11751031
Neuropharmacology. 2014 Jan;76 Pt B:301-19
pubmed: 23973315
Naunyn Schmiedebergs Arch Pharmacol. 1999 Oct;360(4):382-90
pubmed: 10551275
J Neurochem. 2001 Aug;78(3):619-30
pubmed: 11483665
Behav Pharmacol. 1993;4(4):289-312
pubmed: 11224198
J Pharmacol Sci. 2008 Jan;106(1):15-21
pubmed: 18198473
J Neurosci. 2002 Jul 15;22(14):6247-53
pubmed: 12122083
Mol Pharmacol. 2000 Dec;58(6):1271-8
pubmed: 11093763
Brain Res. 2016 Aug 15;1645:46-9
pubmed: 26740406
J Exp Neurosci. 2015 Sep 10;9(Suppl 1):1-10
pubmed: 26525833
Psychopharmacology (Berl). 2004 Oct;176(1):39-49
pubmed: 15138762
Int Rev Neurobiol. 2009;85:29-33
pubmed: 19607959
Neurochem Res. 2005 Apr;30(4):445-51
pubmed: 16076014
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5300-5
pubmed: 11320258
J Neurosci Methods. 2004 Dec 30;140(1-2):169-81
pubmed: 15589347
Pharmacol Biochem Behav. 2000 Nov;67(3):559-66
pubmed: 11164086
Prog Neurobiol. 2010 Apr;90(4):385-417
pubmed: 19941931
Eur J Neurosci. 2004 Dec;20(11):3073-84
pubmed: 15579162
Neuropsychopharmacology. 2008 Feb;33(3):619-26
pubmed: 17487226
Behav Pharmacol. 2014 Apr;25(2):158-65
pubmed: 24557322
J Neurochem. 2003 Jul;86(1):13-24
pubmed: 12807420
Behav Pharmacol. 2015 Feb;26(1-2):167-79
pubmed: 25485646
Behav Pharmacol. 2001 Apr;12(2):109-16
pubmed: 11396515
Int J Neuropsychopharmacol. 1999 Jun;2(2):145-150
pubmed: 11281982
Encephale. 2016 Jun;42(3):255-63
pubmed: 27112704
Neuroscience. 2002;115(1):153-61
pubmed: 12401330
Neurobiol Learn Mem. 2015 Jan;117:51-9
pubmed: 24858182
Behav Pharmacol. 2001 Nov;12(6-7):549-55
pubmed: 11795245
Eur Neuropsychopharmacol. 2004 May;14(3):217-25
pubmed: 15056481
Eur J Pharmacol. 2001 Jun 22;422(1-3):91-9
pubmed: 11430919
Eur J Neurosci. 2000 Jul;12(7):2299-310
pubmed: 10947809
Neurosci Biobehav Rev. 2004 Oct;28(6):565-82
pubmed: 15527863
Pharmacol Rep. 2013;65(4):813-22
pubmed: 24145075
Synapse. 2016 Jul;70(7):293-301
pubmed: 26990537
Psychopharmacology (Berl). 2002 Aug;163(1):9-19
pubmed: 12185395
Pharmacol Rev. 2016 Jul;68(3):816-71
pubmed: 27363441
Curr Top Behav Neurosci. 2010;3:29-71
pubmed: 21161749
PLoS One. 2014 Dec 16;9(12):e115009
pubmed: 25514162
Eur Neuropsychopharmacol. 2002 Oct;12(5):387-96
pubmed: 12208556
Behav Brain Res. 2011 Jun 20;220(1):9-19
pubmed: 21262272
J Chem Neuroanat. 2008 Jul;35(4):356-63
pubmed: 18406571
J Comp Neurol. 2000 Feb 7;417(2):181-94
pubmed: 10660896
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7699-704
pubmed: 9636213
Prog Brain Res. 2008;172:45-71
pubmed: 18772027